- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Edesa Biotech Inc(EDSA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EDSA
11/20/2026: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing novel treatments for inflammatory and immune-related diseases. Its primary strengths lie in its specialized monoclonal antibody pipeline, led by candidate EB05, targeting areas of high unmet medical need. The main investment opportunity centers on potential clinical success and strategic partnerships that could validate its platform. However, the company faces high risks, including clinical trial uncertainties, lack of commercial revenue, and potential equity dilution. It suits high-risk growth investors willing to monitor regulatory updates and trial readouts closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth potential is tied directly to clinical milestone success rather than consistent historical revenue expansion. |
| Momentum investor | Strong fit while signal remains positive | Stock price volatility often spikes dynamically around clinical trial announcements and regulatory news updates. |
| Value investor | Weak fit | The absence of commercial revenue and ongoing cash burn make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for clinical pipeline progression. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial dilution risks create substantial downside volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price movements driven by clinical trial updates. |
| Valuation risk | High | Valuations are speculative and depend heavily on future clinical outcomes rather than current financial output. |
| Competition risk (large cap biopharma competition) | High | Well-funded competitors can develop alternative therapies that surpass Edesa's pipeline candidates. |
| Business quality | Medium | The company possesses specialized scientific assets, but lacks the commercial scale of established players. |
| Dividend income | Low / none | No dividend is paid or anticipated in the foreseeable future. |
| Execution risk | High | Successful execution relies entirely on navigating complex clinical trials and securing regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.39M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 3.0M shares | Beta 1.24 | 52 Weeks Range 0.72 - 20.32 | Updated Date 11/20/2026 |
52 Weeks Range 0.72 - 20.32 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.72 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -4.05% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Therapeutics Development | Future commercialization, out-licensing, or milestone payments derived from drug candidates like EB05 and EB06. | The company currently has no commercial products and does not generate operational revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 0.18 | Enterprise Value 18.84M | Price to Sales(TTM) 130462.29 |
Enterprise Value 18.84M | Price to Sales(TTM) 130462.29 | ||
Enterprise Value to Revenue 140491.25 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 13.51M | Shares Floating 5.04M |
Shares Outstanding 13.51M | Shares Floating 5.04M | ||
Percent Insiders 13.89 | Percent Institutions 58.49 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

